News articles about pSivida (NASDAQ:PSDV) have trended somewhat positive this week, Accern reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. pSivida earned a news sentiment score of 0.13 on Accern’s scale. Accern also gave news coverage about the company an impact score of 45.3502203414988 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the news articles that may have impacted Accern Sentiment’s rankings:
- pSivida (PSDV) Given a $5.00 Price Target at B. Riley (americanbankingnews.com)
- pSivida Corp. (PSDV) Receives Average Rating of “Buy” from Analysts (americanbankingnews.com)
- pSivida (PSDV) Downgraded to “Strong Sell” at ValuEngine (americanbankingnews.com)
- ETFs with exposure to pSivida Corp. : November 30, 2017 (finance.yahoo.com)
- pSivida Corp. :PSDV-US: Earnings Analysis: Q1, 2018 By the Numbers : November 29, 2017 (finance.yahoo.com)
PSDV has been the subject of several research analyst reports. B. Riley set a $5.00 target price on pSivida and gave the stock a “buy” rating in a research note on Monday. HC Wainwright reiterated a “buy” rating and set a $5.00 target price on shares of pSivida in a research note on Wednesday, November 8th. Laidlaw initiated coverage on pSivida in a research note on Wednesday, November 8th. They set a “buy” rating and a $5.00 target price for the company. Finally, ValuEngine downgraded pSivida from a “sell” rating to a “strong sell” rating in a research note on Friday. One research analyst has rated the stock with a sell rating and seven have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $7.57.
pSivida (NASDAQ:PSDV) last released its earnings results on Tuesday, November 7th. The company reported ($0.15) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.15). The firm had revenue of $0.39 million during the quarter, compared to the consensus estimate of $0.74 million. pSivida had a negative return on equity of 139.56% and a negative net margin of 226.31%. sell-side analysts anticipate that pSivida will post -0.58 earnings per share for the current year.
WARNING: This piece was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.com-unik.info/2017/12/05/psivida-psdv-earns-media-sentiment-rating-of-0-13.html.
pSivida Corp. develops drug delivery products primarily for the treatment of chronic eye diseases. The Company operates through the biotechnology sector segment. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert.
What are top analysts saying about pSivida Corp.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for pSivida Corp. and related companies.